{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:40:57Z","timestamp":1787499657557,"version":"build-2736575974"},"reference-count":7,"publisher":"Centers for Disease Control MMWR Office","issue":"36","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm6636a5","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T11:30:28Z","timestamp":1505388628000},"page":"959-960","source":"Crossref","is-referenced-by-count":28,"title":["Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S\/D for Hepatitis A Virus Prophylaxis"],"prefix":"10.15585","volume":"66","author":[{"given":"Noele P.","family":"Nelson","sequence":"first","affiliation":[{"name":"Division of Viral Hepatitis, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2017,9,15]]},"reference":[{"key":"key-10.15585\/mmwr.mm6636a5-201709141129-R1","unstructured":"GamaSTAN S\/D. Package insert. Research Triangle Park, NC: Grifols; 2005. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/UCM371376.pdf"},{"key":"key-10.15585\/mmwr.mm6636a5-201709141129-R2","unstructured":"Important change in prescribing information immune globulin (human): GamaSTAN S\/D https:\/\/www.hypermunes.com\/documents\/24720443\/24803488\/Healthcare+Provider+Letter+GamaSTAN+SD+Revised+Dosage+July+7+2017_with+LIT+CODE.pdf\/b831e517-9d0b-472c-b5b5-719f5bb5e47c"},{"key":"key-10.15585\/mmwr.mm6636a5-201709141129-R3","unstructured":"Kroger AT, Duchin J, V\u00e1zquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/index.html"},{"key":"key-10.15585\/mmwr.mm6636a5-201709141129-R4","article-title":"Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"55","author":"Fiore","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.mm6636a5-201709141129-R5","unstructured":"Council of Europe. European pharmacopoeia. 8th ed. Strasbourg, France: Council of Europe; 2015."},{"key":"key-10.15585\/mmwr.mm6636a5-201709141129-R6","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1001\/jamainternmed.2016.9057","article-title":"Evaluation of potencies of immune globulin products against hepatitis A.","volume":"177","author":"Tejada-Strop","year":"2017","journal-title":"JAMA Intern Med"},{"key":"key-10.15585\/mmwr.mm6636a5-201709141129-R7","first-page":"1080","article-title":"Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"56","author":"CDC","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T11:30:28Z","timestamp":1505388628000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/66\/wr\/mm6636a5.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,15]]},"references-count":7,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2017,9,15]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm6636a5","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,9,15]]},"published":{"date-parts":[[2017,9,15]]}}}